Valuation Models For Large Cap Biopharma Stocks In A Bear Market

We have been in a bear market for biotechnology stocks since September 2015 despite a Q4 rally; now add to that the recent 2016 YTD correction of 16% bringing prices topre-bubble lows
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.